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Abstract
Yeast cells can be killed upon expression of pro-apoptotic mammalian proteins. We have established a functional yeast
survival screen that was used to isolate novel human anti-apoptotic genes overexpressed in treatment-resistant tumors. The
screening of three different cDNA libraries prepared from metastatic melanoma, glioblastomas and leukemic blasts allowed
for the identification of many yeast cell death-repressing cDNAs, including 28% of genes that are already known to inhibit
apoptosis, 35% of genes upregulated in at least one tumor entity and 16% of genes described as both anti-apoptotic in
function and upregulated in tumors. These results confirm the great potential of this screening tool to identify novel anti-
apoptotic and tumor-relevant molecules. Three of the isolated candidate genes were further analyzed regarding their anti-
apoptotic function in cell culture and their potential as a therapeutic target for molecular therapy. PAICS, an enzyme
required for de novo purine biosynthesis, the long non-coding RNA MALAT1 and the MAST2 kinase are overexpressed in
certain tumor entities and capable of suppressing apoptosis in human cells. Using a subcutaneous xenograft mouse model,
we also demonstrated that glioblastoma tumor growth requires MAST2 expression. An additional advantage of the yeast
survival screen is its universal applicability. By using various inducible pro-apoptotic killer proteins and screening the
appropriate cDNA library prepared from normal or pathologic tissue of interest, the survival screen can be used to identify
apoptosis inhibitors in many different systems.
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Introduction
Apoptosis is a common form of programmed cell death
occurring in metazoans that leads to removal of cells in the
organism while avoiding the induction of inflammation [1,2]. Two
distinct but interconnected apoptotic signaling pathways have
been discovered and delineated at the molecular level. The
extrinsic pathway is physiologically triggered by ligands of the
death receptor family, which leads to receptor clustering, assembly
of the cytoplasmic receptor complex DISC (death inducing
signaling complex) and activation of initiator CASPASE-8 and
CASPASE-10 within the DISC platform [3]. The intrinsic
pathway involves the death stimulus-induced release of mitochon-
drial Cytochrome c (CYT c) into the cytoplasm, where it triggers
multimerization of the adaptor protein, APAF-1, and formation of
the apoptosome complex, which ultimately enables CASPASE-9
recruitment and activation [4].
While apoptosis functions to coordinate the elimination of
excess, hazardous or damaged cells under normal physiological
conditions [2,5], alterations in the regulatory mechanisms of cell
death/survival contribute to many human pathological conditions,
including cancer and neurodegenerative diseases, thus highlighting
the importance of maintaining the tight regulation of the apoptotic
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cancer cells are exposed to a variety of strong apoptotic stimuli,
such as oncogene activation, hypoxia and anoikis [7–10]. There-
fore, potent selective pressure may cause unphysiological activa-
tion of survival signals (such as gain-of-function mutations,
overexpression of anti-apoptotic proteins) and accumulation of
loss-of-function mutations (i.e. inactivation of pro-apoptotic tumor
suppressors). Nevertheless, tumor cells are usually more sensitive to
external apoptotic stimuli compared with their non-transformed
counterparts, thereby indicating that despite acquisition of
apoptosis-inhibiting mutations, they are pushed to the edge of
survival by environmental (and proliferative) stresses [11,12]. As a
consequence, first-line chemotherapy and radiation normally
eliminate the primary tumor mass before remaining tumor (stem)
cells acquire additional anti-apoptotic mutations, which render the
cells insensitive to therapeutic intervention [13]. The developing
resistant tumor metastases represent a severe clinical problem and
significantly contribute to the cancer-related death rate [14].
The identification of all relevant anti-apoptotic oncoproteins
and their evaluation for targeted molecular therapy, in combina-
tion with other treatment options, is required to enhance
therapeutic treatments and alternatives. Therefore, we have
developed a functional fission yeast-based survival screen of cDNA
libraries prepared from human tumors to identify novel anti-
apoptotic oncoproteins (over-) expressed in various human tumor
entities. Yeast cells can be efficiently killed by heterologous
overexpression of several pro-apoptotic molecules, including pro-
apoptotic members of the BCL-2 protein family and adaptor
proteins such as CED-4/APAF-1 [15–17]. The specificity of the
process is highlighted by the observation that mutants of the pro-
apoptotic molecules that are incapable of killing mammalian cells
do not induce yeast cell death [15]. In addition, the demise of yeast
cells can be inhibited by co-expression of the appropriate anti-
apoptotic proteins. For example, the co-expression of the
mammalian apoptosis inhibitor, BCL-XL, and the pro-apoptotic
BCL-2 family member, BAK, prevents BAK-induced yeast cell
death [15]. Based on this finding, the unicellular yeast model can
be used as a high throughput screening system to identify
inhibitory molecules that interfere with the yeast cell death
program triggered by a killer protein downstream of the stimulus
or by directly binding and neutralizing the pro-apoptotic protein
[18–20]. Preliminary small-scale screen results have indicated that
a majority of the yeast cell death-suppressing cDNAs are also
capable of inhibiting apoptosis in mammalian cells, thereby
validating the potential of the screening system [21].
We prepared high quality mRNA from primary human tumor
material of various origins, including a lung metastasis of a
melanoma, glioblastoma and therapy-resistant leukemic blasts. By
selecting tumor entities and metastases that are notoriously
resistant to chemotherapy-induced apoptosis [22,23], we increased
the chances of isolating anti-apoptotic proteins that are important
for tumor initiation and the development of therapy resistance.
Such tumor cell death inhibitors may represent attractive novel
targets for molecular therapeutic strategies.
Here, we present the principle and representative results of the
yeast survival screenings, which includes statistics and experi-
mental cell culture and in vivo data for the isolated anti-apoptotic
candidate oncogenes, namely PAICS, MALAT1 and MAST2. The
majority of the library cDNAs isolated from the surviving yeast
colonies interfered with mammalian apoptosis. By demonstrating
the oncogenic potential of the identified genes in human cells both
in cell culture and in vivo, we confirmed the power of this functional
yeast screening system, which can be broadly applied and adapted
to isolate relevant apoptosis inhibitors in all biological and patho-
physiological metazoan systems in which regulation and de-
regulation of apoptosis is very important, such as during
development [24,25] and autoimmunity [26].
Materials and Methods
Ethics statement
Approval of the mouse experiments was obtained prior to
beginning of the research by the Hessian Regional Commission in
Darmstadt, Germany (reference number V54-19c20/15-F123/
33). The procedure of injecting genetically modified human cancer
cell lines into the flanks of NOD/SCID mice and killing the
animals for analytical purposes in the laboratory of Dr. Martin
Zo ¨rnig (Georg-Speyer-Haus, Frankfurt, Germany) was approved
by the animal welfare officer, Dr. Margit Wagenblast.
For the mouse experiments described in this manuscript, 100 ml
of tumor cell suspension were injected once subcutaneously into
the flank of the animals, which had been anesthetized before by
inhalation of isoflurane. Tumors were measured 2–3 times per
week, and when the tumor volume reached 1 cm
3, the animals
were euthanized by sufficient inhalation of isoflurane, followed by
cervical dislocation and removal of the tumor mass for further
analysis.
Yeast and mammalian cell lines
Growth conditions and media for the fission yeast Schizosacchar-
omyces pombe were described previously [27]. The S.pombe yeast
strain DSI was established upon stable transfection of the yeast
expression construct pRIP45-hBAK [15] and HC4 by stable
transfection of pRIP45-CED-4 [16]. In the RIP45 vector,
thiamine-repressable transgene expression is under control of the
nmt-promotor [28,29].
The melanoma cell line MelJuSo (DSMZ (German collection of
microorganisms and cells cultures) no. ACC 74) and the
glioblastoma cell line U87 (ATCC no. HTB-14) were used for
cell culture and in vivo tumor xenograft experiments. The lung
carcinoma cell line A549 (ATCC no. CCL-185) was used to
establish zinc finger nuclease (ZFN)-mediated MALAT1 knockout
cell clones (A549 MALAT1 ko1 and ko2) [30]. Parental A549 cells
and A549-ctr (control) cell clones (with the GFP-polyA expression
cassette randomly integrated; A549-ctr clones exhibited unaffected
MALAT1 levels similar to the parental cells) were used as controls.
Reagents and media
Doxycycline, epoxomicin, lithium acetate (LiOAc), MG132,
phloxine B, polyethylene glycol (PEG; P4000) and thiamine were
purchased from Sigma-Aldrich (Taufkirch, Germany). Recombi-
nant TRAIL was obtained from PeproTech Inc. (Rocky Hill,
USA), and Edinburgh Minimal Medium (EMM), L-leucine, uracil
and yeast extract sucrose (YES) were purchased from MP
Biochemicals (Heidelberg, Germany). Dulbecco’s modified eagles
medium (DMEM) and Roswell Park Memorial Institute (RPMI)
medium (both Invitrogen, Karlsruhe, Germany) were used for
mammalian cell culture.
Tumor-derived yeast expression cDNA libraries
Primary tumor material (a lung metastasis from a primary
melanoma, biopsies from 6 different glioblastomas, and treatment-
resistant leukemic blasts isolated from 6 patients) was used to
isolate high-quality polyA
+ mRNA, which was then reversely
transcribed into full length cDNA, employing the SMART-
method [31]. The cDNA fragments were cloned by directed
insertion into the constitutively active S. pombe expression vector
pART1b [21]. The primers pART1b LCK fw (59-ATCCTTTCG-
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GATGGAGGA-39) were used for sequencing of cDNA inserts.
Functional yeast survival screen
With single DSI [15] and HC4 [16] yeast colonies, for which
cell death following killer protein induction had been confirmed, a
5 ml pre-culture containing 5 mg/ml thiamine was inoculated
overnight while shaking at 30uC. Next, 4 ml of this culture was
added to 150 ml thiamine-containing medium, and following
overnight growth, 100 ml of this stationary phase yeast culture was
mixed with 1 l EMM yeast medium containing either leucine,
uracil and thiamine (DSI) or leucine and uracil without thiamine
(HC4) until they reached an OD595 density of 0.3. Yeast cells were
grown for three hours until they had reached an OD595 of 0.6 and
then harvested by centrifugation at 1,000 g at room temperature
for 5 min. The cell pellet was washed with 800 ml water,
transferred to 15 ml Falcon tubes and centrifuged again. The
resulting yeast pellets were resuspended in 8 ml LiOAc/1xTE and
then transferred to a Falcon tube containing 20 mg denatured
herring sperm carrier-DNA and 150 ml library cDNA (,100 mg).
For transformation of the HC4 strain, 30 ml of library cDNA
(20 mg) were used. Next, 60 ml PEG/LiOAc were added to the
yeast/DNA mixture, and the solution was then divided into two
50 ml Falcon tubes and incubated for 30 min at 30uC, shaking at
150 rpm. 10% DMSO (7 ml) was added and yeast were incubated
in a 42uC water bath for 15 min ‘‘heat-shock’’ with frequent
shaking. Afterwards, yeast cells were kept on ice for 3 min and
then centrifuged for 5 min at 1,000 g at room temperature. The
pellets were resuspended in 6 ml 1xTE buffer and the yeast cell
suspension was distributed and plated on 14.5 cm yeast agar plates
with EMM agar plus uracil and thiamine. For the HC4 screen, the
suspension was plated directly on EMM plates plus uracil (without
thiamine). To estimate the transformation efficiency, 20 to 50 ml
transformed yeast cell aliquots (40–200 ng cDNA) were diluted
with 1xTE and then plated on 10 cm yeast agar plates with EMM
agar plus uracil and thiamine. After four to six days, yeast colonies
from the test plates were counted and transformation efficiencies
were determined. The 14.5 cm screening plates were incubated
for four to six days at 30uC. After apparent colony formation, the
plates were replica plated up to four times on thiamin-free agar
plates with EMM agar plus uracil but without thiamine for the
selection of surviving colonies. Agar plates containing phloxine
(5 mg/ml) were used to allow for better discrimination between
pale living colonies (phloxine-free) and red dead yeast colonies
[32].
shRNA constructs for cellular knockdown experiments
pGIPZ shRNA vectors were purchased from Open Biosystems
(Lafayette, USA; for further information see www.openbiosystems.
com). The non-silencing control vector pGIPZ shctr and the
following three PAICS-specific pGIPZ shRNAs were used for non-
inducible knockdown experiments:
pGIPZ shctr: hairpin 59- TGCTGTTGACAGTGAGC-
GATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCACAG-
ATGTACTTACTCTCGCCCAAGCGAGAGTGCCTACTGCC-
TCGGA -39 (sense and anti-sense sequence are underlined)
pGIPZ sh1PAICS: hairpin 59-TGCTGTTGACAGTGAGC-
GATTTTCTAGCTGCATTTCCTTAGTGAAGCCACA GATG-
TAAGGAAATGCAGCTAGAAAAGTGCCTACTGCCTCGGA-
39
pGIPZ sh2PAICS: hairpin 59- TGCTGTTGACAGT-
GAGCGCGGGCTCCAAATGGTAAAGAAATAGTGAAGCC-
ACAGATGTATTTCTTTACCATTTGGAGCCCTTGCCTAC-
TGCCTCGGA -39
pGIPZ sh3PAICS: hairpin 59-TGCTGTTGACAGTGAGC-
GATCTTAATCTATAAACCATGTAGTGAAGCCACA GAT-
GTACATGGTTTATAGATTAAGAGTGCCTACTGCCTCG-
GA -39
To obtain doxycycline-inducible pTRIPZ shctr and pTRIPZ
sh2PAICS constructs, the short hairpins from the corresponding
pGIPZ vectors were subcloned into pTRIPZ following the Open
Biosystems manual.
pLKO.1-puro vectors from Sigma-Aldrich (Taufkirch, Germany)
were used to downregulate MAST2 expression (sh1MAST2 RNA:
59- CCGGTGTGGACATGGTGCGTCTATACTCGAGTA-
TAGACGCACCATGTCCACATTTTTG -39 (sense and anti-
sense underlined); sh2MAST2 RNA: 59-CCGGGAGGACTTC-
GAGACCATTAAGCTCGAGCTTAATGGTCTCGAAGTCC-
TCTTTTTTG -39; non-silencing control shRNA (shctr): 59-
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTG-
CTCTTCATCTTGTTGTTTTTG -39.
Lentiviral transduction of mammalian cells
HEK 293T cells were seeded (2610
6 cells per 10 cm dish) and
transfected with 5 mg of total DNA (2.5 mg lentiviral construct plus
1.625 mg packaging plasmid p8.91 and 0.875 mg packaging
plasmid pMD2.G, which both encode structural virus proteins)
using the polyethyleneimine method. Virus-containing super-
natant was harvested 48 and 72 hours after transfection and
filtered through a 0.45 mg syringe filter unit. The virus was then
either stored at 4uC for up to one week or, following concentration
by ultracentrifugation, at 280uC for long-term storage. To
concentrate the virus, virus-containing supernatant (max. 30 ml)
was transferred into open-top thinwall polyallomer tubes, and 5 ml
20% sucrose was carefully pipetted into the bottom of each tube as
underlayer. Tubes were then inserted into the pre-cooled
centrifuge rotor buckets and tared. The viral supernatant was
centrifuged for 2 h 20 min at 4uC and 20,500 rpm (51,610 g).
Next, the supernatant was decanted and the tubes were turned
upside down on a tissue for a few seconds to drain the remaining
liquid. The virus particles were dissolved in 200 ml 21 ml of the
desired culture medium for at least 2 h (or overnight) at 4uC. The
concentrated virus was stored at 280uC.
For the transduction of adherent cells, 2610
5 cells per well (6-
well plates) were seeded 24 hours before transduction. The
lentiviral supernatant or concentrated virus was mixed with fresh
medium, polybrene was added with a final concentration of 8 mg/
ml and cells were then spin-infected by centrifugation at 250 g and
32uC for 60 min. After an additional 4 to 6 hours of incubation at
37uC and 5% CO2, the virus-containing medium was removed
and fresh culture medium was added. When the cells had grown to
confluency, they were trypsinized and transferred to 10 cm dishes.
This is referred to as passage zero (P0) post transduction.
cDNA synthesis using the Omniscript RT kit
The Omniscript Reverse Transcriptase kit (Qiagen) was used
for reverse transcription of RNA species according to the
manufacturer’s instructions. Briefly, 1 mg of RNA was transcribed
in a 20 ml reaction mix containing RT reaction buffer, dNTPs,
RNAse inhibitor (RiboLock, Fermentas), reverse transcriptase,
oligo(dT) and random hexamer primers. The reaction mixture was
incubated for 1 h at 37uC.
cDNA synthesis (alternative method)
Long RNA molecules, such as MALAT1, can form secondary
structures that reduce the efficiency of these molecules as templates
in the reverse transcription reaction. To prevent secondary
structure formation, the RNA is pre-heated prior to cDNA
A Yeast Survival Screen to Find Novel Oncoproteins
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64873synthesis and reverse transcription is performed at higher
temperatures with special enzymes optimized for the synthesis of
long cDNAs, such as the RevertAid H Minus Reverse Tran-
scriptase (Fermentas). Next, 1 mg RNA was mixed with 2 ml
random hexamer primers (100 mM) and 12 ml DEPC-H2O,
heated for 5 min at 70uC, cooled on ice and then centrifuged
for 3 sec at 1,800 rpm. A reaction mixture containing 4 ml5 6
RT-buffer, 2 ml dNTP mix (10 mM of each dNTP), 1 ml Ribolock
RNase inhibitor (40 U/ml) and 1 ml RevertAid H minus Reverse
Transcriptase (200 U/ml) was added to the RNA sample and
incubated at 42uC for 1 h. After an additional 10 min incubation
at 70uC, the reaction mixture was transferred to ice and used for
Real-Time PCR analysis.
Quantitative Real-Time PCR (qPCR)
The relative quantification of mRNA transcripts was performed
using the SybrGreen method [33]. The specificity of the qPCR
reaction was verified by assessing the melting curves, via agarose
gel analysis, and sequencing of the isolated reaction product.
cDNA was prepared using either the Omniscript RT kit (Qiagen)
or the above-described alternative protocol. qPCR analysis was
performed using an iCycler iQ (Biorad). Individual samples were
analyzed in triplicate. To compare the relative abundance of
target cDNA in different samples, the DDCt value [34] was
calculated as DDCt = DCt (sample 1)–DCt (sample 2). The fold
difference between each target gene compared with the house-
keeping gene was calculated as 2
2DDCt.
qPCR primer
Knockdown efficiencies were confirmed by quantitative real-
time PCR (see Supplementary material and methods) using the
following primers:
MALAT1 (fw 59- GAATTGCGTCATTTAAAGCCTAGTT -
39, rev 59- GTTTCATCCTACCACTCCCAATTAAT -39)
RN7SL1 (for normalization; fw: 59-ATCGGGTGTCCGCAC-
TAAGTT-39, rev: 59-CAGCACGGGAGTTTTGACCT-39)
MAST2 (fw 59- GGACAAGTAACCGCAAGAGC -39, rev 59-
GAGCAGGTGCATTTGGAGAG-39)
HGPRT (for normalization; fw 59-TGACACTGGCAAAA-
CAATGCA-39, rev 59-GGTCCTTTTCACCAGCAAGCT-39)
Super-SAGE expression analysis
Super-SAGE data for MALAT1 expression in pancreas
carcinoma and pancreatitis compared to normal pancreas tissue
were obtained from GenXPro GmbH (Frankfurt am Main,
Germany; Dr. Bjo ¨rn Rotter) and PD Dr. Christoph Michalski
(Chirurgische Klinik und Poliklinik, Technische Universita ¨t
Mu ¨nchen, Germany).
Western blot analysis
Proteins separated by electrophoresis were transferred onto
0.45 mm nitrocellulose membranes using a semi-dry transfer
system. For immunodetection, the unspecific binding of antibodies
to the nitrocellulose membrane was inhibited via membrane
incubation in blocking buffer for 1 h at room temperature or at
4uC overnight. Membranes were incubated with antiserum at 4uC
overnight and washed three times for 10 min with PBS-T (0.1%
Tween in 16PBS). Secondary antibodies coupled to horseradish
peroxidase were used for membrane incubation for 1 h at room
temperature. After washing the membranes three times for 10 min
with PBS-T, chemiluminescence was assessed using an ECL
detection kit.
Antisera
Induced expression of human BAK and C. elegans CED-4
proteins was confirmed using a polyclonal rabbit anti-BAK
antibody from Santa Cruz (clone H211; sc-7873) and a rabbit
anti-CED-4 antiserum (no. 9104.1, kindly provided by Dr.
Gartner, Wellcome Trust Centre for Gene Regulation and
Expression, University of Dundee, UK; [35]. For detection of
the PAICS protein, immunohistochemical and Western blot
analyses were performed with a self-raised anti-PAICS antiserum.
The serum was retrieved from rabbits immunized with peptide A
(GKKLYEGKTKEVYE; PAICS aa 10–23) and peptide B
(RLWPSGDRSQQKDK; aa 222–235) and was affinity-purified
using both peptides coupled to a column. For Western blot
analysis, equal protein loading was confirmed with an anti-EZRIN
antiserum (clone 3C12; Cat. No 35-7300; Invitrogen), or by
Ponceau S staining of the membrane following protein transfer.
Immunohistochemical analysis
A tissue microarray (TMA) was assembled by obtaining 2–3
tissue cores from conventional paraffin blocks of metastatic
cutaneous malignant melanoma (total: 39 tumors), in addition to
25 cores from normal skin tissue containing epidermal melano-
cytes and epithelium. The cores were embedded into a recipient
TMA block, from which 2 m-sections were cut, mounted on
superfrost glass slides, deparaffinized with xylene and rehydrated
with graded ethanol. A multi-tumor array and a multi-(normal)
tissue array were obtained from the National Center for Tumor
Diseases (NCT Heidelberg, Germany), and the array sections were
treated similar to the melanoma array sections. Slides were
subjected to 5 min heating at 120u C in Tris-EDTA-Buffer pH 8.5
in a pressure cooker. Endogenous peroxidase activity was
quenched by a 5 min incubation with Peroxidase-Blocking
solution (catalog no. s2023, Dako Hamburg, Germany) at room
temperature and afterwards, slides were washed with a wash buffer
for 5 min (catalog no. 3006, Dako Hamburg, Germany). After-
wards, the sections were incubated with a with a self-raised
polyclonal rabbit anti-PAICS antiserum (dilution 1:50) for 30 min
and washed for 5 min with a wash buffer (catalog no. 3006, Dako
Hamburg, Germany). Slides were subsequently incubated with a
labelled polymer (Envision, catalog no. K5007, Dako Hamburg,
Germany) for 30 min and washed for 5 min (catalog no. 3006,
Dako Hamburg, Germany). Antibody binding was visualized using
3,39-diaminobenzidine in chromogen solution (DAB+ Substrate,
catalog no. K 5007, Dako Hamburg, Germany). Tissue sections
were counterstained with hematoxylin (catalog no. 1051750500,
Merck, Darmstadt, Germany).
For MAST2 immunohistochemistry, human cortex tissue and
U87 glioma cells were formalin-fixed and paraffin-embedded. The
use of human tissue was approved by the ethics committee at the
university hospital of Frankfurt. Paraffin blocks were cut with a
microtome (3 mm thickness) and placed on SuperFrost-Plus slides
(Microm International, Walldorf, Germany). A rabbit polyclonal
anti-human MAST2 antibody (dilution 1:50; catalog
no. HPA040155; Sigma, Stockholm, Sweden) was used for
immunohistochemistry. Tissue labelling was performed using the
DiscoveryXT immunohistochemistry system (Ventana/Roche,
Strasbourg, France).
Apoptosis assay
The Nicoletti protocol was used for simultaneous quantification
of apoptosis and cell cycle analysis [36]. First, cells were harvested
and transferred to FACS tubes. After centrifugation (5 min, 400 g,
4uC), the cells were washed with PBS and again spun down by
centrifugation. Cells were fixed by adding 1 ml ice-cold 70%
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least 12 h. Before staining, cells were washed with 38 mM Na-
Citrate (pH 7.4), centrifuged, and 200–400 ml of 38 mM Na-
Citrate containing 50 mg/ml propidium iodide and 5 mg/ml
RNase A was added. Cell staining was performed for 20 min at
room temperature in the dark, and the acquisition of the cell cycle
profiles in the FL2-A channel was performed with a FACS Calibur
(Becton Dickinson Biosciences) using the doublet discrimination
module (DDM) of the CellQuest Pro software (Becton Dickinson
Biosciences).
Colony formation assays
Methyl cellulose colony forming assay. MelJuSo mela-
noma cells lentivirally tranduced with either pTRIPZ shPAICS or
pTRIPZ shctr were treated for 3 days with 1 mg/ml doxycycline.
Next, 16 hours before seeding for the assay, the cells were either
incubated with 0.2 mM staurosporine or left untreated. Duplicates
of 1610
3 MelJuSo cells were then seeded in 35 mm
2 dishes (Nunc)
in MethoCultH H4100 (Stemcell Technologies) in RPMI medium
supplemented with 30% FBS, 3% L-glutamine, 3% penicillin/
streptomycin and 3 mg/ml doxycycline. After 6 days of growth,
red fluorescent colonies were quantified using a microscope.
Crystal violet colony forming assay. The A549 control
GFP cells and two zinc finger nuclease (ZFN)-mediated MALAT1
knockout cell clones were seeded in DMEM/10% FCS medium at
750 cells/well in triplicates in a 6-well plate. The colonies were
allowed to grow for 8 days and were then washed once with PBS
prior to staining and fixing with crystal violet solution (0.5% crystal
violet and 6% glutaraldehyde) for 20 minutes. The plates were
washed twice in distilled water and then dried. Colonies comprised
of 60 cells and more were counted using a 363 cm scoring grid.
Quantification of CASPASE-3-like protease activity
For measuring effector caspase activity, cells were lysed in 200 ml
lysis buffer [10 mM HEPES, pH 7.4, 42 mM KCl, 5 mM MgCl2,
1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM EDTA,
0.1 mM EGTA, 1 mM dithiothreitol (DTT), 1 mg/ml Pepstatin A,
1 mg/ml Leupeptin, 5 mg/ml Aprotinin, 0.5% 3-(3-cholamidopro-
pyldimethylammonio)-1-propane sulfonate (CHAPS)]. Fifty mlo f
this lysate were added to 150 ml reaction buffer (25 mM HEPES
pH 7.5, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, 3 mM DTT).
The fluorogenic substrate Ac-DEVD-AMC was added at a final
concentration of 10 mM. Accumulation of AMC fluorescence was
monitored over two hours using an HTS fluorescent plate reader
(excitation 380 nm, emission 465 nm). Protein content was
quantified using the RotiH-Quant Coomassie Plus Protein Assay
reagent (Roth, Karlsruhe, Germany). The caspase activity is
expressed as a change in fluorescence units per mg protein and hour.
Cell expansion assay
The total cell number and the number of viable cells in a sample
were determined using a CASYH Cell Counter (Scha ¨rfe Systems,
Reutlingen, Germany). The appropriate measurement program
was established using Casyblue according to the manufacturer’s
instructions. For measurement, 25 ml cell suspension aliquots were
transferred to a CASYH cup containing 10 ml CASYHton, mixed
by inverting three times and placed in the CASYH Cell Counter.
Click-iTH EdU cell proliferation assay
S-phase analysis was performed with a BD FACS Calibur using
the Click-iTH EdU Flow Cytometry Assay Kit (Alexa 488;
Molecular Probes; #C35002) according to the manufacturer’s
instructions.
Xenograft tumor mouse model
NOD-SCID mice (6 to 10 weeks old) were used for xenograft
transplantation experiments. Three days before transplantation,
mice were shaved on the back (right flank). Mice were anesthetized
by isoflurane inhalation, and 5610
6 human cancer cells (in 100 ml
PBS) were injected subcutaneously into the right flank. For the
MelJuSo pTRIPZ PAICS shRNA and pTRIPZ ctr shRNA cells,
mice received drinking water containing 2 mg/ml doxycycline and
10 g/l sucrose ad libitum until the end of the experiment to induce
the PAICS shRNA-mediated knockdown. For the subcutaneous
U87 xenograft model, a 100 ml cell suspension, containing 5610
6
U87 cells with or without MAST2 knockdown in 20 ml matrigel
(BD Bioscience) and 80 ml PBS, was injected into each animal.
Matrigel suspensions were kept on ice to avoid clogging of the
injecting needle. Tumor growth was measured 2–3 times per week
with a manual caliper. Mice were sacrificed when they developed
ulcerating tumors or developed a xenograft tumor larger than
1c m
3. The tumor size was calculated as follows: tumor volume
[mm
3] = length 6width
2 60.5.
Statistics
All statistical analyses were performed with GraphPad Prism 5.0
from GraphPad Software Inc. (La Jolla, USA). Data were
presented as mean 6 standard error of the mean (SEM) if not
indicated otherwise. Two-tailed student’s t-test (two group
comparisons) or one-way-ANOVA analysis (multiple group
comparisons) were performed, and statistical significance was
indicated with * for p,0.05, ** for p,0.01 or *** for p,0.001.
Results
Screening of human tumor-derived cDNA expression
libraries in BAK- and CED-4-expressing S.pombe yeast
strains
We used S. pombe fission yeast in a high throughput screening
system to identify novel human anti-apoptotic oncoproteins. The
principle of the screen, which is outlined in Fig. 1A, is based on
the observation that the unicellular yeast organism can be killed
upon heterologous (over-) expression of pro-apoptotic mammalian
proteins [15]. To achieve inducible expression of death-inducing
pro-apoptotic ‘‘killer’’ proteins in yeast cells, we cloned the human
pro-apoptotic BCL-2 family member, BAK, into the thiamine-
repressible S. pombe expression vector pRIP45 and stably integrated
the construct into the S. pombe genome. The resulting yeast strain,
DSI (BAK), displayed significant killer protein expression following
thiamine removal (see Fig. 1B) and died with great efficiency after
three rounds of replica plating on thiamine-free yeast agar plates.
In previous experiments, we had demonstrated quantitative cell
death in the DSI strain in liquid culture 24 hours after BAK
induction [15].
Additionally, we used another S. pombe yeast strain with
inducible killer protein expression, HC4, in which the C. elegans
homologue of APAF-1, CED-4 [37], had been cloned into the
pRIP45 vector and stably integrated. The HC4 cells express
elevated levels of CED-4 upon thiamine removal (Fig. 1C),
thereby leading to rapid and complete yeast cell death as
quantified in re-plating experiments [38]. The HC4 yeast strain
was originally used to functionally investigate the C. elegans cell
death machinery [16]. APAF-1 and CED-4 are structurally and
functionally conserved, and ectopic CED-4 expression induces
mammalian cell death which is inhibited by BCL-xL over-
expression [39]. Therefore, we used HC4 cells to screen for
inhibitors of mammalian mitochondrial apoptosis. We have
previously identified the APAF-1-binding anti-apoptotic protein
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HC4 strain [38].
In parallel, we isolated high-quality mRNA (polyA
+ RNA) from
primary human tumor samples of various origins (a lung metastasis
from a primary melanoma, biopsies from 6 different glioblastomas
and treatment-resistant leukemic blasts isolated from 6 patients).
The polyA
+-RNA was reverse transcribed into cDNA using the
SMART approach, a method that enriches for cDNAs represent-
ing full-length transcripts [31]. Size-selected cDNA (larger than
400 bp) were cloned into the constitutively active S. pombe
expression vector, pART1b, which harbors a different autotrophic
marker compared with the pRIP45 vector (leucine instead of adenine).
As a shuttle vector, it is also suitable for amplification in E. coli
bacteria.
The cDNA libraries were transformed into the DSI and HC4
yeast strains, which had been previously grown in thiamine-
containing repressive medium to harvest the required cell
numbers. To increase the selective pressure and reduce the
number of surviving yeast colonies, we transferred the DSI and
HC4 cells into liquid yeast medium without thiamine 6 hours
before library transformation, leading to earlier expression of BAK
and CED-4. The transformed yeast cells were plated on thiamine-
free agar plates to continuously induce killer protein expression.
After an additional replica plating three times on thiamine-free
agar plates, all non-protected yeast cells died, while a few death-
resistant yeast colonies continued to grow.
The surviving yeast colonies were collected and individually
expanded to isolate the transformed library plasmids, which were
then directly transformed into bacteria for plasmid amplification.
DNA sequencing revealed the identity of the library inserts.
Occasionally, a surviving yeast colony contained two different
library plasmids, in which case either insert could have been
responsible for the inhibition of cell death.
Figure 1. Principle of the yeast survival screen. A. Two S. pombe yeast strains were established with inducible expression of the pro-apoptotic
proteins BAK and CED-4, following thiamine removal from the growth medium. Killer protein expression resulted in efficient yeast cell death upon
plating onto thiamine-deficient yeast agar plates. Transformation of the yeast cells with a tumor-derived cDNA library led to survival of few killer
protein-expressing yeast colonies from which the yeast cell death-inhibiting library cDNA insert was identified and analyzed for its anti-apoptotic
potential in mammalian cells and expression levels in tumor biopsies. B,C. Inducible expression of human BAK (B) and C. elegans CED-4 (C) in yeast S.
pombe. Total cell lysates were prepared from the parental yeast (wildtype), DSI- and HC4-strains cultured in thiamine-containing medium or after
cultivation for 20 hours in thiamine-free medium. Subsequently, Western blot analysis was performed. Human BAK was detected with a polyclonal
rabbit anti-BAK antibody (Santa Cruz, Heidelberg, Germany). Anti-CED-4 antiserum (9104.1, kindly provided by A. Gartner, University of Dundee, UK)
was used at a 1:500 dilution to detect C.elegans CED-4 expression. Ponceau S staining is presented as a protein loading control.
doi:10.1371/journal.pone.0064873.g001
A Yeast Survival Screen to Find Novel Oncoproteins
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64873Statistical analysis of the survival screenings
All three survival screens with cDNAs derived from melanoma
metastasis, leukemia and glioblastoma yielded similar statistical
results. Here, data from the melanoma screen are shown as a
representative example (see Fig. 2 for overview).
The overall complexity of the library was 1.8610
6 cfu (bacterial
colony number after initial transformation of the ligated cDNA
library prior to primary amplification). Transformation of the
cDNA library into yeast resulted in 8.6610
5 DSI and 5.9610
5
HC4 yeast colonies, which were then screened for survival
following the induction of killer protein expression. Ultimately,
3,000 (DSI) and 1,800 (HC4) surviving and growing colonies were
observed on thiamine-free agar plates. We selected 116 DSI and
133 HC4 colonies for expansion and sequencing of the library
inserts and identified 79 (DSI) and 77 (HC4) human genes,
respectively. Fewer genes were identified than yeast colonies used
for library plasmid extraction because a number of genes was
identified several times in the same screen (partly with non-
identical cDNA sequences; see Table 1 and Table S1), including
MALAT1 from the leukemia screen (10 cDNA clones), and B2M
from three screens (identified 6 times in glioblastoma, 6 times in
melanoma with the HC4 strain, and 9 times in melanoma with the
DSI strain). The latter represents one of several examples in which
a gene was isolated from the same tumor-derived cDNA library in
both yeast strains expressing the killer proteins CED-4 and BAK.
Other examples include HIGD1A and PAICS (both found in the
melanoma library). The group of genes isolated in more than one
survival screen (Table S1) included B2M (found in the
glioblastoma and melanoma libraries), MALAT1 (identified in the
melanoma and leukemia libraries, in both cases exclusively with
the CED4-expressing HC4 yeast strain) and SPCS2 (found in the
melanoma and leukemia libraries). In addition, a few inserts
represented yeast DNA instead of human (tumor-derived) cDNA.
Moreover, for a limited number of sequences, BLAST searches
resulted in ‘‘no significant gene alignment’’.
When we included the results from the leukemia and the
glioblastoma screens, the results totaled 240 yeast cell death-
repressing human genes, some of which were isolated in more than
one of the survival screens (i.e., in different tumor entities).
Without such overlap, we obtained 204 non-identical human
genes found in at least one of the three survival screens that were
capable of suppressing yeast cell death (the complete list of
identified genes is shown in Table S1). As a number of genes were
independently isolated several times, either in the same screen or
in independent screenings with different libraries or yeast strains
(Table 1), the results demonstrated the functional stringency of
the survival screen.
Following extensive PubMed literature searches, we allocated
the 204 identified genes into the following groups: 58 genes have
already been described with anti-apoptotic properties, 72 genes
are known to be upregulated in at least one tumor entity, and 33
genes have already been published as both anti-apoptotic and
upregulated in cancer. Meanwhile, the remaining 86 genes have
not been described to play a role in apoptosis and/or cancer until
now. The high number of isolated genes already known to be
involved in the regulation of apoptosis and cancer serves as a
convincing internal control for the quality of the screen, which was
designed to identify anti-apoptotic oncogenes expressed in primary
tumor material.
Examples for all four groups of identified genes are shown in
Table 2. The class of verified anti-apoptotic molecules over-
expressed in cancer includes prominent tumor-associated proteins
such as b-Catenin (CTNNB1) (for review see [40,41]), Osteopon-
tin (OPN/SPP1) (for review see [42]), BMI1 (for review see [43]),
Peroxiredoxin 3 (PRDX3; [44]) and DAD1 [45]. Their anti-
apoptotic and tumor-promoting influence upon (over-) activation
is well established.
In the group of genes involved in the regulation of apoptosis but
without published links to tumorigenesis, established inhibitors of
apoptosis such as PPP1CC [46] were identified, again confirming
that the yeast-based survival screen allows for the identification of
tumor proteins that efficiently suppress apoptosis in human cells.
The third class of isolated yeast cell death suppressors includes
molecules such as PAICS [47], STEAP1 [48–50] and MALAT1
[51–53], for which overexpression and/or functional relevance in
tumor biology has been published.
Figure 2. Statistics of the melanoma metastasis screen. The cDNA library prepared from a lung metastasis of a melanoma patient was
transformed into the BAK (DSI) and CED-4 (HC4)-expressing yeast strains for subsequent survival screenings. Of the 8.6610
5 plated DSI yeast colonies,
3,000 colonies survived the killer protein expression; of these, 116 were sequenced and further analyzed. Meanwhile, from the 5.9610
5 plated CED-4
yeast colonies, 1,800 colonies survived the killer protein expression, and of these, 133 were sequenced and analyzed.
doi:10.1371/journal.pone.0064873.g002
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esis and/or apoptosis; although, some aspects of their physiological
function are either known (e.g., MAST2 [54–56] and NUDT5
[57,58]) or the molecules remain completely undescribed (e.g.,
FAM36A and PRRC1).
The expression data for the selected candidate genes
reveals strong and frequent overexpression in various
human tumors
Literature searches have revealed that our yeast survival screen
of tumor-derived cDNA libraries indeed selects for anti-apoptotic
cDNAs with functional links to tumorigenesis. To assess whether
some of the death-suppressing genes isolated in the survival screen
are overexpressed in tumor entities, we performed a variety of
tumor expression studies analyzing the three selected candidate
genes. These genes were all overexpressed in certain tumor entities
according to the Oncomine database (www.oncomine.org; the
database offers gene expression analysis results based on several
thousand cancer transcriptome profiles), and they displayed
interesting characteristics regarding tumorigenesis and potential
cancer therapy. With PAICS, we selected one enzyme of a
pathway already successfully targeted by methotrexate during
tumor treatment. MALAT1 is a prominent member of the heavily
investigated family of long non-coding RNAs, which is over-
expressed in a variety of tumors. Finally, MAST2 is a kinase
associated with microtubules and is involved in intracellular
signaling: kinases represent attractive druggable targets for cancer
therapy.
PAICS
PAICS (Phosphoribosylaminoimidazole carboxylase/phosphor-
ibosylaminoimidazole succino-carboxamide synthetase) was iden-
tified in the melanoma lung metastasis screen. The molecule is a
bi-functional enzyme of the de novo purine biosynthesis pathway
with both 5-aminoimidazole ribonucleotide carboxylase and 4-(N-
Table 1. Numeric overview of the survival screen.
Gene characteristics Number of genes % of total
total 204 100.0
anti-apoptotic 58 28.4
upregulated in cancer 72 35.3
anti-apoptotic + upregulated in cancer 33 16.2
Gene overlap Number of genes % of total
multiple clone hits 41 20.1
multiple screen hits 14 6.9
As listed in the upper portion of the table, the identified genes were grouped into the following categories: total = number of all identified genes from melanoma
metastasis, leukemia and glioblastoma screens; anti-apoptotic = number of isolated genes for which anti-apoptotic properties have been published; upregulated in
cancer = number of genes that are upregulated in at least one tumor entity; anti-apoptotic + upregulated in cancer = number of anti-apoptotic genes upregulated in
at least one tumor entity. The bottom portion of the table displays the number of genes, for which more than one clone was identified (multiple clone hits) and the
number of genes for which clones were identified from at least two different cDNA libraries.
doi:10.1371/journal.pone.0064873.t001
Table 2. Classification of genes isolated by yeast survival screens based on their involvement in apoptosis regulation and
tumorigenesis.
Apoptosis/Cancer
HMGB1 Osteopontin ß-Catenin BMI1
SGK1 CCL2 PRDX3 EIF4B
UBE2V1 NUP107 TC1 DAD1
Apoptosis
CALM2 STAM2 ERO1L PPP1CC
Cancer
PAICS NAP1L1 STEAP1 MALAT1
No link to Apoptosis/Cancer
MAST205 NUDT5 SSR1 VPS29
FAM36A ZCCHC10 C8orf40 PRRC1
From the 204 genes identified in the functional yeast survival screens of melanoma metastasis-, leukemia- and glioblastoma-derived cDNA libraries, a representative
selection of 28 was chosen and grouped into four categories as follows: (1) ‘‘Apoptosis/Cancer’’ includes genes that have been described to possess anti-apoptotic
properties and are implicated in tumorigenesis (minimal requirement: upregulated in tumors). (2) ‘‘Apoptosis’’ includes genes with published anti-apoptotic properties
(but until now were not recognized to be upregulated in cancer or involved in tumorigenesis). (3) ‘‘Cancer’’ encompasses genes that are expressed at higher levels in
tumors than in healthy samples (but have not been shown to play a role in apoptosis regulation). (4) ‘‘No link to Apoptosis/Cancer’’ includes genes without published
links to apoptosis or cancer.
doi:10.1371/journal.pone.0064873.t002
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activities. Cancer cells rely on the PAICS-dependent metabolic
pathway for AMP and GMP synthesis, while untransformed cells
recover purines via the salvage pathway ([59] and references
herein). Inactivation of the de novo pathway (e.g. by the antifolate
drug methotrexate) inhibits cancer cell proliferation both in vitro
and in vivo [60].
Analysis of the Oncomine database demonstrated that PAICS
mRNA is significantly overexpressed in a variety of tumor entities,
including colorectal cancer, brain and CNS cancer, bladder
cancer and lymphoma (Fig. 3A). The highest level of over-
expression was observed in a squamous cell lung carcinoma
(SCLC) study, with a 19-fold increase in PAICS mRNA expression
compared with normal tissue. We then developed a peptide-
derived anti-human PAICS antiserum (see Fig. S1 for specificity
control by Western blot analysis) for immunohistochemical (IHC)
analysis of several tumor entities represented on a multi-tumor
array. IHC analysis revealed significant PAICS protein over-
expression in melanoma samples compared with normal skin
biopsies; this result was confirmed when the IHC analysis was
repeated with a cohort of 39 melanomas in which the PAICS
expression levels were compared with 25 normal skin samples
(Fig. 3B).
MALAT1
MALAT1 (metastasis associated lung adenocarcinoma transcript
1) is a long non-coding RNA of 8.7 kb that functions in mRNA
splicing [61] and has been reported to be strongly overexpressed in
various human solid carcinomas, including lung, breast, pancreas,
colon, prostate, endometrial stromal sarcoma and HCC (for
references see [53]). For stage I non-small cell lung cancers
(NSCLC), high MALAT1 expression levels have been described to
correlate with metastasis [52,62].
We isolated several MALAT1 cDNA clones from the melanoma-
and leukemia-derived tumor libraries. Our Oncomine search
confirmed MALAT-1 overexpression in various tumor entities
(Fig. 3A), with the highest levels of MALAT-1 overexpression
observed in rectal mucinous adenocarcinoma (6-fold overexpres-
sion compared with normal tissue). RNA expression data obtained
by Super-SAGE (serial analysis of gene expression) revealed 1.3- to
3.8-fold MALAT-1 overexpression in chronic pancreatitis, pan-
creatic adenocarcinomas and intraductal papillary mucinous
tumors compared with normal pancreas tissue (Fig. 3C).
MAST2
Microtubule associated serine/threonine kinase 2 (MAST2/
MAST205) is a 205-kDa serine/threonine kinase that is associated
with microtubules [63] and plays an important role in the
regulation of LPS-induced cytokine response of macrophages [56].
MAST2 has also been reported to form a complex with TRAF6,
thereby resulting in the inhibition of NF-kB activation ([55] and
references herein). MAST2 represents the founding member of the
MAST protein family consisting of MAST1-4 [64]. All family
members are characterized by the presence of the serine/
threonine kinase and PDZ domains. Somatic alterations of MAST
genes have not previously been described to play a role in cancer
development. Several expression studies submitted to Oncomine
have demonstrated MAST2 mRNA overexpression in esophageal
cancer, pancreatic cancer and sarcomas (Fig. 3A).
Collectively, our tumor expression analysis of PAICS, MALAT-1
and MAST2 confirmed the overexpression of all three genes in
various tumor entities, thereby supporting the tumor relevance of
candidate genes isolated by functional yeast survival screenings of
tumor-derived cDNA libraries.
In vitro downregulation of selected candidate genes in
several tumor cell lines results in increased apoptosis and
decreased proliferation
Because we isolated PAICS from the melanoma metastasis
cDNA library and found PAICS protein levels to be upregulated
in melanomas, we targeted PAICS expression in the human
melanoma cell line MelJuSo by lentiviral transduction with three
different PAICS shRNA sequences cloned into the pGIPZ vector.
MelJuSo and other established melanoma cell lines express
prominent amounts of PAICS protein exceeding the PAICS levels
observed in the spontaneously immortalized human keratinocyte
cell line HaCaT and in human foreskin fibroblast cells (see Fig.
S2A). Efficient PAICS downregulation in MelJuSo cells by the
shRNAs was confirmed by Western blot analysis after puromycin
selection (see inlet in Fig. 4A). As shown in Fig. 4A, all MelJuSo
PAICS knockdown cell lines showed increased levels of staur-
osporine-induced apoptosis compared with control shRNA-
transduced cells. MelJuSo cells transduced with sh2PAICS shRNA
were then analyzed in further cell death assays following apoptosis
induction by various apoptotic stimuli. Treatment of PAICS
knockdown in MelJuSo cells with cisplatin, mitomycin C,
staurosporine and etoposide led to increased apoptosis in
comparison to control shRNA-transduced cells (Fig. S3A). For
cisplatin and staurosporine, this difference was statistically
significant.
We then used the PAICS knockdown MelJuSo cell lines for a cell
counting experiment. Fig. 4B shows significantly lower cell
expansion rates for all three PAICS shRNA MelJuSo cell lines
compared to the control shRNA-transduced cells. As no significant
difference in the apoptosis rate of untreated PAICS and control
shRNA-transduced cells was observed (Fig. 4A), this difference in
cell expansion may be attributed to decreased proliferation rather
than increased apoptosis.
In the absence of puromycin selection, the knockdown of PAICS
vanished with increasing numbers of passages, indicating a strong
selective pressure against the loss of PAICS in the cells. Therefore,
we introduced a doxycycline-inducible PAICS shRNA system
(using the sh2PAICS shRNA sequence) into MelJuSo cells, which
allowed for a complete knockdown of PAICS mRNA following 3
days of doxycycline treatment. Six days after removal of
doxycycline from the medium, the cells expressed normal PAICS
levels (Fig. S4). MelJuSo cells expressing the inducible PAICS
knockdown vector system were again used for a cell counting
experiment. The increase in viable cells was identical in non-
induced PAICS- and control shRNA-transduced cells in the
absence of doxycycline. However, upon the knockdown of PAICS
in the presence of doxycycline, the cells expanded significantly
slower and almost stopped proliferating (see Fig. S3B).
To further investigate the tumorigenicity of the PAICS-deficient
MelJuSo cells and analyze the influence of PAICS on anchorage-
independent growth, we seeded MelJuSo cells with wildtype
PAICS level or cells with induced PAICS knockdown in semi-solid
methyl cellulose and subsequently quantified colony growth after 6
days. We performed this assays with both untreated healthy cells
and cells treated with staurosporine. In both cases, the colony
numbers were significantly reduced in the absence of PAICS,
thereby confirming that PAICS plays an important role in the
tumorigenicity of melanoma cells (see Fig. S5A).
MALAT1 expression was originally associated with metastasis in
NSCLC patients and described as an adverse prognostic
parameter for patient survival during stage I NSCLC [52,62].
We selected the human lung carcinoma cell line, A549, to
investigate the in vitro consequences of MALAT1 deficiency for
apoptosis sensitivity and proliferation potential. A549 cells express
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produced by the house keeping gene GAPDH [52,62]. Knockdown
via RNAi is insufficient for such levels of nuclear ncRNA. In
previous work with several MALAT1 siRNA sequences, we have
achieved a knockdown efficiency of 13% residual MALAT1 RNA
levels [30]. However, because of the high MALAT1 expression
levels in A549 cells, the substantial residual expression of MALAT1
could mask its loss-of-function phenotype and prevent the
functional characterization of MALAT1. To generate MALAT1-
deficient cells for functional analyses, we used a zinc-finger
nuclease (ZFN) and integrated RNA-destabilizing elements (RDE)
into the human MALAT1 gene locus [30]. Biallelic RDE
integration resulted in a 1000-fold reduction in RNA expression
levels, which represents a far greater reduction compared with that
achieved by shRNA-mediated knockdown of the abundant
MALAT1 molecules in A549 cells (Fig. S6A). Interestingly,
MALAT1 deficiency led to a significant increase in apoptosis
sensitivity in A549 cells treated with staurosporine and cisplatin
(Fig. 4C), which correlates with an apoptosis-inhibiting function
of MALAT1. However, absence of MALAT1 did not influence the
expansion of cells, thereby suggesting that proliferation was not
affected by removal of MALAT1 (data not shown).
To perform an additional cell culture-based assessment of the
tumorigenicity of cells in either the presence or absence of
MALAT1 RNA, we seeded GFP-expressing control A549 cells and
the two ZFN-mediated A549 MALAT1 knockout cell clones at a
low density and subsequently counted the colonies after 8 days
using crystal violet staining. As shown in Fig. S5B, the knockout
of MALAT1 resulted in a significant decrease in clonogenicity and
Figure 3. Enhanced expression of selected candidate genes in various tumor entities. A. mRNA expression analysis using the open access
cancer microarray database Oncomine. The table displays the overall number of microarray analyses present in the database that show upregulation
of PAICS, MALAT1 or MAST2 in the tumor type listed in the table. The Oncomine search was performed with the thresholds as follows: p-value , 1E-4,
fold change .2, and gene rank = top 10%. B. An immunohistochemical staining of PAICS protein expression was performed with purified anti-
hPAICS serum on 25 normal skin and 39 melanoma slides. Examples of a normal skin and a melanoma result are presented; the table at the bottom
summarizes the results. The average expression level of PAICS protein in normal skin was low, while PAICS expression ranged between moderate
(mod) and high in a majority of the melanoma biopsies. The unpaired, two-tailed Mann-Whitney test revealed significant differences between
melanoma and normal skin IHC scores (p,0.0001). C. Super-SAGE expression analysis of normal and diseased pancreatic tissues revealed significant
upregulation of MALAT1 in chronic pancreatitis, pancreatic adenocarcinoma and intraductal papillary mucinous tumors compared with normal
pancreas. The experiment was performed with RNA pools from 4 healthy pancreas samples, 3 chronic pancreatitis biopsies, 4 ductal
adenocarcinomas and 5 intraductal papillary mucinous tumors.
doi:10.1371/journal.pone.0064873.g003
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in sustaining the transformed phenotype of the tumor cells.
MAST2 was isolated from the glioblastoma cDNA library. The
protein is significantly expressed in the glioblastoma cell line U87,
whereas MAST2 expression is absent in human cortex tissue,
which consists of many astrocytes, probably constituting the cells-
of-origin for glioblastoma (see Fig. S2B). To investigate its
oncogenic potential in vitro, we suppressed MAST2 expression in
U87 cells via lentiviral shRNA transduction and subsequently
selected for two stable knockdown cell lines (MAST2 mRNA
expression levels are presented in Fig. S6B). Following co-
treatment with TRAIL and two different proteasome inhibitors (a
promising combination for future glioblastoma therapy [65]), the
apoptotic profile of MAST2 shRNA U87 cells was assessed and we
observed a significant increase in apoptosis sensitivity in the
absence of MAST2 (Fig. 4D), thereby confirming the anti-
apoptotic potential of this kinase. We also noticed a decrease in
cell proliferation upon knockdown of MAST2 as measured by
quantification of EdU incorporation during DNA synthesis (Fig.
S7; note that the U87 MAST2 knockdown cell line with the lower
amount of remaining MAST2 mRNA proliferated even less than
the second MAST2 knockdown cell line). Both the anti-apoptotic
and pro-proliferative molecular functions observed suggest that
MAST2 behaves as an oncoprotein in glioblastoma.
Figure 4. Increased apoptosis sensitivity and decreased proliferation in PAICS, MALAT1 and MAST2 knockdown cells. A. MelJuSo
melanoma cells with stable pGIPZ shRNA-mediated PAICS knockdown (sh1-3PAICS) and control shRNA (shctr)-transduced cells were incubated for
24 hours with 0.2 mM staurosporine. Apoptosis was quantified by FACS using the Nicoletti protocol [36], and data are presented as the mean 6 SEM,
n=4. Efficient knockdown of PAICS was confirmed in Western blot analysis using an anti-PAICS antiserum (inlet). B. Cell expansion kinetics of MelJuSo
cells upon pGIPZ shRNA-mediated PAICS knockdown (sh1-3PAICS). Viable cells were quantified using a CASY cell counter, and cell numbers were
compared with cells transduced with a non-targeting control shRNA (shctr). Data represent the mean values 6 SEM, n=3. One-way-ANOVA testing
with Bonferroni multi-comparison correction was performed. The significance is indicated by stars for the comparison of shctr versus sh1-3PAICS (*: p-
value ,0.05; ***: p-value ,0.001). The PAICS knockdown efficiencies were analyzed via immunoblotting (see inlet Fig. 4A). C. Apoptosis assays using
the Nicoletti FACS protocol were performed with parental A549 cells (wt), control GFP cells (ctr) and two zinc finger nuclease technology (ZFN)-
mediated MALAT1 knockout cell clones (ko1 and ko2) [30]. Results are shown for both untreated cells and cells incubated for 16 hours with either
1 mM staurosporine or 400 mM cisplatin. Data are presented as the mean 6 SEM (n=6), One-way-ANOVA testing with Bonferroni multi-comparison
correction was applied, and statistical significance is indicated as **: p,0.01, ***: p,0.001. Confirmation of the MALAT1 knockout is presented in Fig.
S6A. D. Two stable pGIPZ-mediated MAST2 knockdown cell lines were established from parental U87 cells (for evaluation of the knockdown
efficiencies, see Fig. S6B), and following incubation of the cells with DMSO (solvent control), recombinant TRAIL (250 ng/ml), MG132 (2,5 mM),
epoxomicin (50 nM), TRAIL plus MG132, and TRAIL plus epoxomicin for 16 h, apoptosis was quantified in a CASPASE-3 activity assay. Control shRNA-
transduced U87 cells served as a control. Data are presented as the mean 6 SEM (n=4), One-way-analysis of variance (ANOVA) testing with
Bonferroni multi-comparison correction was applied, and statistical significance is indicated as ***: p,0.001.
doi:10.1371/journal.pone.0064873.g004
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mouse model leads to diminished tumor growth
To obtain further experimental in vivo evidence that the
candidate genes isolated in the functional yeast survival screen
play an important oncogenic role in tumor progression, we utilized
both the U87 MAST2 and inducible MelJuSo PAICS knockdown
tumor cell lines (used previously in cell culture assays) in a
xenograft tumor mouse model.
When we injected U87 cells stably transduced with either
sh2MAST2 or control shRNA subcutaneously into the right flank
of immunodeficient NOD/SCID mice, we observed a significant
delay in tumor growth in the sh2MAST2 animals (see Fig. 5A).
This observation demonstrates that MAST2 plays an important
role in glioblastoma growth by suppressing apoptosis and
increasing cellular proliferation.
We also analyzed the consequences of PAICS deficiency in
MelJuSo melanoma cells using a subcutaneous xenograft tumor
model. Because the constitutive PAICS knockdown was unstable in
MelJuSo cells (see above), we used cells with a doxycycline-
inducible PAICS knockdown for the xenograft experiment.
Tumors were grown without PAICS-specific shRNA expression
until they reached a volume of 50 mm
3. The mice then received
drinking water supplemented with doxycycline to induce PAICS
knockdown. Fig. 5B shows the relative tumor growth for PAICS
and control knockdown cells in relation to the tumor volume at the
beginning of doxycycline treatment. The PAICS knockdown
tumors grew significantly slower compared with the control cells
with normal PAICS expression. Fig. 5C displays the relative
tumor size calculated as the tumor volume of the PAICS
knockdown tumors divided by the tumor volume of the control
shRNA-transduced cells. The data suggest that the differences in
tumor growth shown in Fig. 5B are primarily caused by an initial
arrest of tumor growth directly following the induction of the
PAICS knockdown. However, after day 5 of doxycycline treatment,
the PAICS and control knockdown tumors grew with comparable
kinetics (horizontal progression of the curve in Fig. 5C). The
PAICS knockdown tumors failed to re-express the PAICS protein
as shown in Fig. 5D. Interestingly, the tumor cells quickly adapted
to growth in the absence of PAICS, possibly by switching to the
salvage pathway for purine biosynthesis.
Discussion
In recent years, the concept in cancer therapy to specifically
target tumor cells while sparing the untransformed normal cells
has gained much attraction. This is not only due to reduced side
effects for the patient and higher success rates, but also because
immune effector cells remain unaffected by cytotoxicity and can
help to eradicate the tumor [66]. A better understanding of all
deregulated molecular players that induce oncogenic signaling in
tumors would enhance future therapeutic options by denoting new
targets. Moreover, the successful analysis of their function will
allow for the application of specified therapeutics such as
personalized cancer treatment [67].
Tumor cells survive by withstanding a plethora of different
apoptosis stimuli. The acquirement of apoptosis resistance by loss-
of-function (pro-apoptotic tumor suppressors) or gain-of-function
(anti-apoptotic oncoproteins) mutations is an important hallmark
of tumorigenesis [7]. Therefore, the interference with anti-
apoptotic signaling in tumor cells is considered a promising
cancer therapy strategy [68]. The functional yeast survival screen
described in this manuscript exploits the genetically well-defined
yeast system to screen cDNA libraries in a high throughput format
for novel anti-apoptotic proteins. In principle, the screen can be
adapted to identify apoptosis inhibitors of a variety of biological
systems. By selecting the appropriate killer protein to induce yeast
cell death, as well as generating and screening cDNA libraries
from the relevant tissue or cellular source, anti-apoptotic proteins
regulating various biological processes, such as embryonic
development or tissue homeostasis in the adult organism, can be
isolated. Another interesting application is the identification of
(deregulated) apoptosis inhibitors from diseased tissues (cancer,
infection or auto-immunity). Here, we used cDNA libraries
prepared from various tumor entities (lung metastasis of a primary
melanoma, glioblastoma and leukemic blasts) to identify novel
anti-apoptotic oncoproteins that are involved in tumorigenesis
and/or therapy resistance. We also performed proof-of-principle
experiments to evaluate a few of the identified apoptosis regulators
as molecular cancer therapy targets.
Of the 204 genes identified in the three screens, 28% were
already known to inhibit apoptosis according to the literature,
35% were described as upregulated in expression databases in at
least one tumor entity, and 16% of the genes were described both
as anti-apoptotic in function and overexpressed in tumors
(Table 1). These genes represent the class of molecules we aimed
to identify and they served as a positive control, validating the
screening system. Furthermore, 42% of the isolated genes had not
been previously described to play a role in apoptosis or
tumorigenesis; these genes represented the pool of potential novel
anti-apoptotic oncoproteins. These results demonstrate the power
of the functional survival screen to identify tumor-relevant
apoptosis inhibitors.
We decided to analyze the anti-apoptotic potential and the
oncogenic properties of three of the identified candidate genes,
PAICS, MALAT1 and MAST2. Whereas PAICS [47] and MALAT1
[51] have already been shown to be involved in tumorigenesis,
there are no publications describing the involvement of MAST2 in
apoptosis regulation or cancer.
Our Oncomine database searches revealed an overexpression of
PAICS, MALAT1 and MAST2 mRNA in various tumor entities.
According to the literature, MALAT1 is strongly overexpressed in a
variety of tumor types, including hepatoblastomas [69], hepato-
cellular carcinomas [53,70], breast cancer [71], and endometrial
stromal sarcomas [72]. It has also been described as a metastasis-
associated factor in NSCLC and colorectal cancer [52,73].
Oncomine database entries revealed that MALAT1 overexpression
has been observed in brain and CNS cancer as well as head and
neck cancer. We isolated MALAT1 from our screens of melanoma
metastasis- and leukemic blasts-derived cDNA libraries, while
Super-SAGE expression analysis of the long non-coding MALAT1
RNA expression profile detected a 4-fold increase in pancreas
carcinoma compared with normal tissue.
Upregulation of PAICS has been reported for lung squamous
cell carcinoma [47], and our Oncomine database research yielded
several expression studies in various tumor entities (e.g., brain and
CNS cancer, bladder cancer, colorectal cancer, head and neck
cancer and lung cancer) in which PAICS mRNA was upregulated
compared with corresponding normal tissue. We isolated PAICS
from a screen of the melanoma metastasis-derived cDNA library
in both yeast strains expressing CED-4 and BAK. We subse-
quently confirmed that PAICS protein is overexpressed in
melanomas when compared with normal skin using an anti-
PAICS antiserum.
Although MAST2 has not been previously associated with
apoptosis regulation and tumorigenesis, according to the Oncomine
database, MAST2 mRNA is overexpressed in esophageal cancer,
pancreatic cancer and sarcoma samples.
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apoptotic potential of all three candidate genes. Stable knockdown
of PAICS increased the sensitivity of melanoma cells to cisplatin
and staurosporine treatment. Moreover, using stable and inducible
PAICS knockdown systems in MelJuSo cells, we observed a marked
decrease in cell expansion following PAICS depletion. The
mechanism by which an enzyme of the de novo purine biosynthesis
pathway influences apoptosis sensitivity at the molecular level
remains elusive. The expression levels of several key apoptosis
regulators (CASPASE-3, CASPASE-9, BAX, BAK, BCL-2, BCL-
XL and AIF) did not change upon the induced knockdown of
PAICS (Figure S8). The zinc finger nuclease-mediated knockout
of MALAT1 led to a marked increase in apoptosis sensitivity in
A549 lung cancer cells following incubation with staurosporine
and cisplatin. Stable knockdown of MAST2 resulted in significantly
enhanced cell death in U87 glioblastoma cells upon co-treatment
with TRAIL and the proteasome inhibitors MG132 and
epoxomicin. These data confirm the potential of the survival
screen to isolate cDNAs that inhibit cell death in tumor cells.
The xenograft tumor mouse model data supports the notion
that MAST2 protein is required for tumor progression, possibly
because of its anti-apoptotic potential. Stable knockdown of
MAST2 in U87 cells strongly diminished tumor growth in
immunocompromised mice (Fig. 5A). Interestingly, during
preparation of this manuscript, recurrent gene rearrangements
involving MAST2 and MAST1 were identified in breast cancer cell
lines and tissues [74]. The overexpression of these MAST2 and
MAST1 gene fusions displayed a proliferative effect; however, the
function and (tumor) biology of the wildtype MAST proteins were
not further investigated. Our data demonstrate an increase in
apoptosis sensitivity and diminished tumor growth upon MAST2
Figure 5. Xenograft tumor growth of MAST2 and PAICS knockdown in U87 and MelJuSo cells, respectively. A. The subcutaneous
xenograft tumor growth of stable sh2MAST2 knockdown U87 cells was quantified with a manual caliper 2-3 times per week and compared with non-
targeting control shRNA (shctr)-transduced cells. Data are presented as the mean 6 SEM. 5 mice/group were injected into the right flank. The
unpaired, two-tailed t-test was performed individually for each day after injection of the tumor cells and revealed the following p-values: day 23,
0.0063; day 25, 0.0063; day 28, 0.0169; day 30, 0.0127; day 32, 0.0219; day 34, 0.0496. B. pTRIPZ sh2PAICS-transduced MelJuSo were injected
subcutaneously into the right flank of NOD-SCID mice. When the xenografted tumors reached a size of 50 mm
3, mice received drinking water
containing 2 mg/ml doxycycline and 10 g/l sucrose ad libitum until the end of the experiment to induce the PAICS shRNA knockdown. The graph
displays the relative tumor growth (tumor volumes from day x/day 0 of doxycycline treatment). Injected mice per group: shctr =10, sh2PAICS =11.
Data are presented with the mean values and error bars indicate SEM. The unpaired, two-tailed t-test was performed individually for each day after
the start of doxycycline treatment and revealed significant differences for day 4 to day 28 with doxycycline treatment (day 4, 0.0028; day 7, 0.0163;
day 11, 0.0024; day 14, 0.0082; day 18, 0.0414; day 21, 0.0429; day 25, 0.0311; day 28, 0.0414). In C, the relative tumor size is shown (calculated as
tumor volume of sh2PAICS MelJuSo cells divided by tumor volume of shctr cells). D. Three xenograft tumors per shRNA used (shctr, sh2PAICS) were
isolated, and PAICS protein levels were analyzed via Western blot. In contrast to the MelJuSo cells grown in cell culture (see Fig. 4B), an additional
40-kDa band appeared in the anti-PAICS Western Blot when the lysates were prepared from MelJuSo tumors grown in mice. As with the original 37-
kDa PAICS band, this larger signal disappeared in the PAICS knockdown cells, thereby arguing that it represents a posttranslationally modified PAICS
isoform.
doi:10.1371/journal.pone.0064873.g005
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function for this poorly analyzed kinase.
The induced knockdown of PAICS in MelJuSo melanoma cells
also decreased tumor xenograft growth; however, the difference
compared with tumor growth of the parental cell line with
endogenous PAICS expression was rather small (Fig. 5B).
Apparently, the tumor cells stopped proliferating for the first
couple of days following PAICS depletion before they resumed
expansion (Fig. 5C). Analysis of the outgrown tumors revealed
that the tumor cells maintained a stable PAICS knockdown. It is
quite likely that the MelJuSo cells switch back to the salvage
pathway for purine biosynthesis following the blockage of the de
novo synthesis pathway. Based on these results, the bi-functional
PAICS enzyme might only represent a reasonable target for
molecular therapies in certain tumors, possibly those with an
inactivated/mutated salvage pathway for purine biosynthesis.
We also performed xenograft tumor experiments with MALAT1
knockdown A549 lung cancer cells. However, we did not observe
significant differences in tumor growth without further treatment,
thereby arguing against a significant involvement of MALAT1 in
A549 primary tumor growth. Nevertheless, we confirmed that
MALAT1 plays an important role in tumor metastasis using an
A549 metastasis mouse model [75].
In summary, our data confirm the power of the functional yeast
survival screen to isolate novel anti-apoptotic genes regulating cell
death [18–21]. The success of the screen is based on several
characteristics. As proteins regulating programmed cell death are
functionally conserved among species, the well-characterized yeast
genetics can be used to screen in a high throughput modus. The
screen is also based on functional readout (survival) and can be
customized by selecting the appropriate killer protein and cDNA
library. With these characteristics, it can be adapted to answer a
variety of (patho-) biological questions involving the identification
of programmed cell death inhibitors.
Supporting Information
Figure S1 Validation of self-raised rabbit anti-PAICS
antiserum. Two peptides derived from human PAICS (aa 10–23
and aa 222–235) were simultaneously used for rabbit immuniza-
tion. The antigen-purified anti-PAICS serum was employed for
Western blot analysis of cell lysates from HEK 293T and RKO
cells, which had been transduced with either pSIEW-PAICS or
pSIEW-Flag-PAICS (A, B; non-transduced cells served as a control
for endogenous PAICS) or with the empty vector control (293T
pSIEW; C). The anti-PAICS antiserum recognizes both endogen-
ous PAICS and overexpressed Flag-PAICS protein (A and B), and
the latter was confirmed using anti-Flag antibody (C). Anti-EZRIN
served as a loading control.
(TIF)
Figure S2 Relative expression levels of PAICS and
MAST2 in MelJuSo and U87 cells. A. Western blot analysis
of PAICS protein levels in MelJuSo and other melanoma cell lines
compared to primary human foreskin fibroblasts (HFFC) and the
immortalized normal keratinocyte cell line HaCaT. Following
protein transfer, the membrane was stained with Ponceau S to
confirm equal protein loading, prior to incubation with the self-
raised anti-PAICS antiserum. B. Immunhistochemical analysis of
MAST2 protein levels in human cortex (left panel; scale bar
=100 mm) and U87 cells (right panel). In normal human brain
samples, MAST2 expression was virtually absent from both
neuronal and glial cells. Most U87 glioma cells show moderate to
strong MAST2 expression.
(TIF)
Figure S3 Increased apoptosis and decreased prolifera-
tion in MelJuSo cells upon PAICS knockdown. A. MelJuSo
melanoma cells with stable pGIPZ sh2RNA-mediated PAICS
knockdown and control shRNA (shctr)-transduced cells were
analyzed in apoptosis assays. Untreated cells and cells incubated
for 24 hours with 400 mM cisplatin, 50 mM etoposide, 0.2 mM
staurosporine or 5 mg/ml mitomycin C were analyzed by FACS
using the Nicoletti protocol [36]. Data are presented as the mean
6 SEM, n=3 (paired, two-tailed t-test, **: p-value,0.01). The
PAICS knockdown was confirmed by Western blot analysis (see
inlet of Fig. 4A). B. Cell growth of MelJuSo cells upon initiation of
a pTRIPZ sh2RNA-mediated inducible PAICS knockdown. Viable
cells were quantified using a CASY cell counter. All cells were
incubated with doxycycline to induce shRNA expression, and cell
numbers were compared with parental non-transduced wildtype
cells as well as to cells transduced with a non-targeting control
shRNA (shctr). Data represent the mean values with SEM, n=3.
One-way-ANOVA testing with Bonferroni multi-comparison
correction was performed. The significance is indicated by
asterisks for the comparison of shctr versus sh2PAICS (***: p-
value,0.001). PAICS protein levels were assessed via immuno-
blotting of cells with (Doxy +;s h PAICS expressed) and without
(Doxy -; no shPAICS expression) doxycycline treatment. Anti-Ezrin
served as a loading control. ctr: cells transduced with control
shRNA; kd: cells transduced with pTRIPZ sh2PAICS.
(TIF)
Figure S4 Inducible PAICS knockdown in MelJuSo cells.
MelJuSo cells were transduced with the inducible shRNA vector
pTRIPZ sh2PAICS. Doxycycline treatment induced the expression
of both the turbo red fluorescent protein (tRFP) and PAICS-specific
shRNA. A depicts images of pTRIPZ sh2PAICS-transduced
MelJuSo cells after three days of doxycycline treatment (+3d)
and images of the same cell culture after six days of doxycycline
withdrawal (26d). The upper panel represents transmitted-light
images, while the lower panel displays red fluorescence images
showing tRFP expression. B. A Western blot membrane incubated
with anti-PAICS antiserum, which visualizes PAICS protein levels
in cells without shRNA induction by doxycycline, and after both
three and six days of incubation with 1 mg/ml doxycycline
(induction of shRNA expression). Cell lysates prepared after three
and six days of doxycycline withdrawal were also analyzed. Equal
protein loading was confirmed by anti-EZRIN staining.
(TIF)
Figure S5 Colony formation assays with PAICS knock-
down and MALAT1 knockout tumor cell lines. A. After
pre-treatment for 3 days in medium with 1 mg/ml doxycycline,
2.5610
3 MelJuSo cells stably transduced with pTRIPZ sh2PAICS
or shctr were seeded in methyl cellulose containing 40% RPMI
medium (supplemented with 30% FCS, 3% penicillin/streptomy-
cin and 3 mg/ml doxycycline). For the induction of apoptosis, the
cells were incubated with 0.2 mM staurosporine 16 hours before
seeding. Colony growth was quantified after 6 days. B. A549 cells
(7.5x10
2 cells per well) were plated in normal DMEM/10% FCS
medium in triplicate in 6-well plates, and the colonies were
allowed to grow for 8 days. GFP control cells were compared with
the zinc-finger nuclease-mediated MALAT1 knockout clones, ko1
and ko2. The colonies were fixed and stained with crystal violet
solution and counted in a 363 cm scoring grid. The experiments
were performed three times, and the results are represented as
mean 6 SEM. *p,0.05; **p,0,01; one-way ANOVA analysis
with Bonferroni multi-comparson correction.
(TIF)
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MALAT1 knockout and MAST2 shRNA knockdown U87
cells. A. The residual MALAT1 RNA levels expressed in A549-
ZFN-MALAT1-knockout cells (ko1 and ko2) were compared with
both control (ctr; cells with random GFP integration) and parental
A549 (wt) cells by Real Time qPCR analysis. Data are presented
as mean values 6 SEM (n=3) on a logarithmic scale (log10). B.
The lentiviral MAST2 shRNA knockdown in U87 cells with two
different MAST2 shRNA sequences was confirmed via qPCR in
comparison with non-targeting control shRNA-transduced U87
cells. Relative MAST2 mRNA expression levels are presented from
a single experiment. GAPDH and HPRT mRNA expression were
used for relative quantification of MAST2 expression.
(TIF)
Figure S7 Quantification of proliferation upon shRNA-
mediated knockdown of MAST2. The two U87 MAST2
knockdown cell lines sh1MAST2 and sh2MAST2 were compared
to control vector-transduced cells for their proliferation rate using
the Click-iTH Edu Proliferation Assay kit (Alexa Fluor 488, Life
Technologies). Cells were incubated with EdU for one hour, and
the percentage of EdU-positive cells was quantified by FACS
analysis. Data are presented as the mean values 6 SEM
(sh2MAST2: n=3; sh1MAST2,s h ctr: n=4).
(TIF)
Figure S8 Expression levels of several apoptosis reg-
ulators in either the presence or absence of PAICS. The
melanoma cell line, MelJuSo, was stably transduced with the
lentiviral construct, pTRIPZ sh2PAICS, and the downregulation of
PAICS was induced using doxycycline. 50 mg (per lane) of protein
lysate was loaded to the gel and Western Blot analyses were
performed either as described in the manuscript (for CASPASE-9)
or using the Odyssey system (for all other proteins). The following
antibodies were used: self-raised anti-PAICS antiserum (see
manuscript), anti-CASPASE-3 (Cell Signaling, #9662), anti-
CASPASE-9 (Alexis, #ALX-210-838-R100), anti-BAX (Upstate,
#06-499), anti-BAK (Santa Cruz, #sc832, clone G-23), anti-BCL-
xL (Cell Signaling, #2764, clone 54H6), anti-BCL-2 (Santa Cruz,
#sc509, clone 100), anti-AIF (Chemicon, #AB16501), anti-PARP
(Cell Signaling, #9542) and anti-GAPDH (Calbiochem,
#CB1001). The following secondary antibodies were used with
the Odyssey system: IRDye 680CW goat anti-rabbit (LI-COR,
#926-32221) and IRDye 800CW goat anti-mouse (LI-COR,
#926-32210).
(TIF)
Table S1 Complete list of genes identified by functional yeast
survival screening of cDNA libraries derived from a melanoma
metastasis, leukemia samples and glioblastomas.
(PDF)
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